Recombinant protein diannexin prevents preeclampsia-like symptoms in a pregnant mouse model via reducing the release of microparticles
Han Guo1, Yuncong Zhang2, Yaxin Chu1, Shuo Yang1, Jie Zhang1, Rui Qiao1()
1. Laboratory Medicine, Peking University Third Hospital, Beijing 100191, China 2. Department of Clinical Laboratory, Peking University International Hospital, Beijing 102206, China
Preeclampsia (PE) is characterized by placenta-mediated pregnancy complication. The only effective treatment for PE is the delivery of the placenta. However, this treatment may cause preterm birth and neonatal death. Therefore, preventing PE is needed. The mechanism of PE involves abnormal placentation, which leads to the release of anti-angiogenic and inflammatory mediators into maternal circulation. These mediators contribute to systemic vascular dysfunction, inflammatory responses, and excessive thrombin generation. Microparticles (MPs) are reportedly involved in PE by promoting the thromboinflammatory response. This study describes a strategy to prevent PE by reducing MP release using the recombinant protein, diannexin. Results showed that the patients with PE had elevated MP number and procoagulant activity and increased NLRP3 inflammasome activation. Additionally, diannexin remarkably reduced the release of MPs from activated cells by binding to phosphatidylserine exposed on the surface of activated cells. Moreover, in vivo results showed that diannexin could prevent PE-like symptoms by decreasing MPs and NLRP3 inflammasome activation in pregnant mice. Furthermore, diannexin effectively inhibited trophoblast cell activation and NLRP3 inflammasome activation in vitro. These findings suggested that diannexin inhibited MP release and might be an effective therapeutic strategy for preventing PE.
. [J]. Frontiers of Medicine, 2022, 16(6): 919-931.
Han Guo, Yuncong Zhang, Yaxin Chu, Shuo Yang, Jie Zhang, Rui Qiao. Recombinant protein diannexin prevents preeclampsia-like symptoms in a pregnant mouse model via reducing the release of microparticles. Front. Med., 2022, 16(6): 919-931.
MA Brown, LA Magee, LC Kenny, SA Karumanchi, FP McCarthy, S Saito, DR Hall, CE Warren, G Adoyi, S; International Society for the Study of Hypertension in Pregnancy (ISSHP) Ishaku. The hypertensive disorders of pregnancy: ISSHP classification, diagnosis & management recommendations for international practice. Pregnancy Hypertens 2018; 13: 291–310 https://doi.org/10.1016/j.preghy.2018.05.004
pmid: 29803330
JT Henderson, EP Whitlock, E O’Connor, CA Senger, JH Thompson, MG Rowland. Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U. S. Preventive Services Task Force. Ann Intern Med 2014; 160(10): 695–703 https://doi.org/10.7326/M13-2844
pmid: 24711050
5
T Chaiworapongsa, P Chaemsaithong, L Yeo, R Romero. Pre-eclampsia part 1: current understanding of its pathophysiology. Nat Rev Nephrol 2014; 10(8): 466–480 https://doi.org/10.1038/nrneph.2014.102
pmid: 25003615
6
EA Phipps, R Thadhani, T Benzing, SA Karumanchi. Pre-eclampsia: pathogenesis, novel diagnostics and therapies. Nat Rev Nephrol 2019; 15(5): 275–289 https://doi.org/10.1038/s41581-019-0119-6
pmid: 30792480
H Shao, H Im, CM Castro, X Breakefield, R Weissleder, H Lee. New technologies for analysis of extracellular vesicles. Chem Rev 2018; 118(4): 1917–1950 https://doi.org/10.1021/acs.chemrev.7b00534
pmid: 29384376
10
C Simon, DW Greening, D Bolumar, N Balaguer, LA Salamonsen, F Vilella. Extracellular vesicles in human reproduction in health and disease. Endocr Rev 2018; 39(3): 292–332 https://doi.org/10.1210/er.2017-00229
pmid: 29390102
11
Y Zhang, C Zhao, Y Wei, S Yang, C Cui, J Yang, J Zhang, R Qiao. Increased circulating microparticles in women with preeclampsia. Int J Lab Hematol 2018; 40(3): 352–358 https://doi.org/10.1111/ijlh.12796
pmid: 29520961
12
M Salem, S Kamal, W El Sherbiny, AA Abdel Aal. Flow cytometric assessment of endothelial and platelet microparticles in preeclampsia and their relation to disease severity and Doppler parameters. Hematology 2015; 20(3): 154–159 https://doi.org/10.1179/1607845414Y.0000000178
pmid: 25001068
13
VanWijk MJ, Nieuwland R, Boer K, van der Post JA, VanBavel E, Sturk A. Microparticle subpopulations are increased in preeclampsia: possible involvement in vascular dysfunction? Am J Obstet Gynecol 2002; 187(2): 450–456 doi:10.1067/mob.2002.124279
pmid: 12193942
14
S Kohli, S Ranjan, J Hoffmann, M Kashif, EA Daniel, MM Al-Dabet, F Bock, S Nazir, H Huebner, PR Mertens, KD Fischer, AC Zenclussen, S Offermanns, A Aharon, B Brenner, K Shahzad, M Ruebner, B Isermann. Maternal extracellular vesicles and platelets promote preeclampsia via inflammasome activation in trophoblasts. Blood 2016; 128(17): 2153–2164 https://doi.org/10.1182/blood-2016-03-705434
pmid: 27589872
15
JI Zwicker, CC 3rd Trenor, BC Furie, B Furie. Tissue factor-bearing microparticles and thrombus formation. Arterioscler Thromb Vasc Biol 2011; 31(4): 728–733 https://doi.org/10.1161/ATVBAHA.109.200964
pmid: 21252066
16
PE Rautou, AS Leroyer, B Ramkhelawon, C Devue, D Duflaut, AC Vion, G Nalbone, Y Castier, G Leseche, S Lehoux, A Tedgui, CM Boulanger. Microparticles from human atherosclerotic plaques promote endothelial ICAM-1-dependent monocyte adhesion and transendothelial migration. Circ Res 2011; 108(3): 335–343 https://doi.org/10.1161/CIRCRESAHA.110.237420
pmid: 21164106
17
WL Van Heerde, P Lap, S Schoormans, PG de Groot, CPM Reutelingsperger, TM Vrooms. Localization of annexin A5 in human tissues. Annexins 2004; 1: 37–43
18
L Ungethüm, H Kenis, GA Nicolaes, L Autin, S Stoilova-McPhie, CP Reutelingsperger. Engineered annexin A5 variants have impaired cell entry for molecular imaging of apoptosis using pretargeting strategies. J Biol Chem 2011; 286(3): 1903–1910 https://doi.org/10.1074/jbc.M110.163527
pmid: 21078669
19
H Kenis, H van Genderen, A Bennaghmouch, HA Rinia, P Frederik, J Narula, L Hofstra, CP Reutelingsperger. Cell surface-expressed phosphatidylserine and annexin A5 open a novel portal of cell entry. J Biol Chem 2004; 279(50): 52623–52629 https://doi.org/10.1074/jbc.M409009200
pmid: 15381697
20
NC Teoh, Y Ito, J Field, NW Bethea, D Amr, MK McCuskey, RS McCuskey, GC Farrell, AC Allison. Diannexin, a novel annexin V homodimer, provides prolonged protection against hepatic ischemia-reperfusion injury in mice. Gastroenterology 2007; 133(2): 632–646 https://doi.org/10.1053/j.gastro.2007.05.027
pmid: 17681182
21
ML Rand, H Wang, FG Pluthero, AR Stafford, R Ni, N Vaezzadeh, AC Allison, WH Kahr, JI Weitz, PL Gross. Diannexin, an annexin A5 homodimer, binds phosphatidylserine with high affinity and is a potent inhibitor of platelet-mediated events during thrombus formation. J Thromb Haemost 2012; 10(6): 1109–1119 https://doi.org/10.1111/j.1538-7836.2012.04716.x
pmid: 22463102
22
H Ueki, T Mizushina, T Laoharatchatathanin, R Terashima, Y Nishimura, D Rieanrakwong, T Yonezawa, S Kurusu, Y Hasegawa, B Brachvogel, E Pöschl, M Kawaminami. Loss of maternal annexin A5 increases the likelihood of placental platelet thrombosis and foetal loss. Sci Rep 2012; 2(1): 827 https://doi.org/10.1038/srep00827
pmid: 23145320
23
V Gourvas, N Soulitzis, A Konstantinidou, E Dalpa, O Koukoura, D Koutroulakis, DA Spandidos, S Sifakis. Reduced ANXA5 mRNA and protein expression in pregnancies complicated by preeclampsia. Thromb Res 2014; 133(3): 495–500 https://doi.org/10.1016/j.thromres.2013.12.027
pmid: 24393658
24
E Shomer, S Katzenell, Y Zipori, RN Sammour, B Isermann, B Brenner, A Aharon. Microvesicles of women with gestational hypertension and preeclampsia affect human trophoblast fate and endothelial function. Hypertension 2013; 62(5): 893–898 https://doi.org/10.1161/HYPERTENSIONAHA.113.01494
pmid: 24082057
25
E Biró, CA Lok, CE Hack, der Post JA van, MC Schaap, A Sturk, R Nieuwland. Cell-derived microparticles and complement activation in preeclampsia versus normal pregnancy. Placenta 2007; 28(8–9): 928–935 https://doi.org/10.1016/j.placenta.2007.02.008
pmid: 17433833
26
K Omatsu, T Kobayashi, Y Murakami, M Suzuki, R Ohashi, M Sugimura, N Kanayama. Phosphatidylserine/phosphatidylcholine microvesicles can induce preeclampsia-like changes in pregnant mice. Semin Thromb Hemost 2005; 31(3): 314–320 https://doi.org/10.1055/s-2005-872438
pmid: 16052403
27
S Baig, N Kothandaraman, J Manikandan, L Rong, KH Ee, J Hill, CW Lai, WY Tan, F Yeoh, A Kale, LL Su, A Biswas, S Vasoo, M Choolani. Proteomic analysis of human placental syncytiotrophoblast microvesicles in preeclampsia. Clin Proteomics 2014; 11(1): 40 https://doi.org/10.1186/1559-0275-11-40
pmid: 25469110
28
S KohliB Isermann. Placental hemostasis and sterile inflammation: new insights into gestational vascular disease. Thromb Res 2017; 151(Suppl 1): S30–S33 doi:10.1016/S0049-3848(17)30063-4
pmid: 28262230
29
M Tong, Q Chen, JL James, PR Stone, LW Chamley. Micro- and nano-vesicles from first trimester human placentae carry Flt-1 and levels are increased in severe preeclampsia. Front Endocrinol (Lausanne) 2017; 8: 174 https://doi.org/10.3389/fendo.2017.00174
pmid: 28790977
30
SJ Germain, GP Sacks, SR Sooranna, IL Sargent, CW Redman. Systemic inflammatory priming in normal pregnancy and preeclampsia: the role of circulating syncytiotrophoblast microparticles. J Immunol 2007; 178(9): 5949–5956 https://doi.org/10.4049/jimmunol.178.9.5949
pmid: 17442979
31
M Messerli, K May, SR Hansson, H Schneider, W Holzgreve, S Hahn, C Rusterholz. Feto-maternal interactions in pregnancies: placental microparticles activate peripheral blood monocytes. Placenta 2010; 31(2): 106–112 https://doi.org/10.1016/j.placenta.2009.11.011
pmid: 20005571
32
C Han, C Wang, Y Chen, J Wang, X Xu, T Hilton, W Cai, Z Zhao, Y Wu, K Li, K Houck, L Liu, AK Sood, X Wu, F Xue, M Li, JF Dong, J Zhang. Placenta-derived extracellular vesicles induce preeclampsia in mouse models. Haematologica 2020; 105(6): 1686–1694 https://doi.org/10.3324/haematol.2019.226209
pmid: 31439676
33
S Ravassa, A Bennaghmouch, H Kenis, T Lindhout, T Hackeng, J Narula, L Hofstra, C Reutelingsperger. Annexin A5 down-regulates surface expression of tissue factor: a novel mechanism of regulating the membrane receptor repertoir. J Biol Chem 2005; 280(7): 6028–6035 https://doi.org/10.1074/jbc.M411710200
pmid: 15576370
34
P Thiagarajan, CR Benedict. Inhibition of arterial thrombosis by recombinant annexin V in a rabbit carotid artery injury model. Circulation 1997; 96(7): 2339–2347 https://doi.org/10.1161/01.CIR.96.7.2339
pmid: 9337209
35
FA Kuypers, SK Larkin, JJ Emeis, AC Allison. Interaction of an annexin V homodimer (diannexin) with phosphatidylserine on cell surfaces and consequent antithrombotic activity. Thromb Haemost 2007; 97(3): 478–486 https://doi.org/10.1160/TH06-08-0436
pmid: 17334517
36
V Combes, SL Latham, B Wen, AC Allison, GE Grau. Diannexin down-modulates TNF-induced endothelial microparticle release by blocking membrane budding process. Int J Innov Med Health Sci 2016; 7: 1–11 https://doi.org/10.20530/IJIMHS_7_1-11
pmid: 28149531
37
Y Zhou, W Cai, Z Zhao, T Hilton, M Wang, J Yeon, W Liu, F Zhang, FD Shi, X Wu, P Thiagarajan, M Li, J Zhang, JF Dong. Lactadherin promotes microvesicle clearance to prevent coagulopathy and improves survival of severe TBI mice. Blood 2018; 131(5): 563–572 https://doi.org/10.1182/blood-2017-08-801738
pmid: 29162596
38
JT Powell, DS Tsapepas, ST Martin, MA Hardy, LE Ratner. Managing renal transplant ischemia reperfusion injury: novel therapies in the pipeline. Clin Transplant 2013; 27(4): 484–491 https://doi.org/10.1111/ctr.12121
pmid: 23614480
39
KE Wever, FA Wagener, C Frielink, OC Boerman, GJ Scheffer, A Allison, R Masereeuw, GA Rongen. Diannexin protects against renal ischemia reperfusion injury and targets phosphatidylserines in ischemic tissue. PLoS One 2011; 6(8): e24276 https://doi.org/10.1371/journal.pone.0024276
pmid: 21918686
40
EY Cheng, VK Sharma, C Chang, R Ding, AC Allison, DB Leeser, M Suthanthiran, H Yang. Diannexin decreases inflammatory cell infiltration into the islet graft, reduces β-cell apoptosis, and improves early graft function. Transplantation 2010; 90(7): 709–716 https://doi.org/10.1097/TP.0b013e3181ed55d8
pmid: 20634785
41
K Hashimoto, H Kim, H Oishi, M Chen, I Iskender, J Sakamoto, A Ohsumi, Z Guan, D Hwang, TK Waddell, M Cypel, M Liu, S Keshavjee. Annexin V homodimer protects against ischemia reperfusion-induced acute lung injury in lung transplantation. J Thorac Cardiovasc Surg 2016; 151(3): 861–869 https://doi.org/10.1016/j.jtcvs.2015.10.112
pmid: 26725713
42
NC Teoh, H Ajamieh, HJ Wong, K Croft, T Mori, AC Allison, GC Farrell. Microparticles mediate hepatic ischemia-reperfusion injury and are the targets of diannexin (ASP8597). PLoS One 2014; 9(9): e104376 https://doi.org/10.1371/journal.pone.0104376
pmid: 25222287
43
IC Weel, M Romão-Veiga, ML Matias, EG Fioratti, JC Peraçoli, VT Borges, JP Jr Araujo, MT Peraçoli. Increased expression of NLRP3 inflammasome in placentas from pregnant women with severe preeclampsia. J Reprod Immunol 2017; 123: 40–47 https://doi.org/10.1016/j.jri.2017.09.002
44
Z Liu, X Zhao, H Shan, H Gao, P Wang. MicroRNA-520c-3p suppresses NLRP3 inflammasome activation and inflammatory cascade in preeclampsia by downregulating NLRP3. Inflamm Res 2019; 68(8): 643–654 https://doi.org/10.1007/s00011-019-01246-8
pmid: 31143973
45
Q Qiu, Z Yang, F Cao, C Yang, P Hardy, X Yan, S Yang, W Xiong. Activation of NLRP3 inflammasome by lymphocytic microparticles via TLR4 pathway contributes to airway inflammation. Exp Cell Res 2020; 386(2): 111737 https://doi.org/10.1016/j.yexcr.2019.111737
pmid: 31759058
